This site is intended only for healthcare professionals resident in India
Menu
Close
Menu
Close
Burden of Disease
Burden of Disease
Risk Factors
Secondary Infections
Mechanism of Action
Prevention of Pneumococcal Disease
Need for Pneumococcal Vaccination
Cost-effectiveness of PCV13
Legacy of Prevenar
Safety
Conclusion
Dosing
Prevenar 13® Clinical Experience
Efficacy of Prevenar 13®
Effectiveness of Prevenar 13®
Indian Clinical Trials
Recommendations for Use
PCV13 in Pulmonology
PCV13 in Nephrology
PCV13 in Oncology
PCV13 in Rheumatology
PCV13 in Diabetes
PCV13 in HIV Infection
PCV13 in Cardiology
Resources
The Indian society of Nephrology released its guidelines in 2016 for the vaccination of patients with CKD and kidney transplant recipients.
Recommendations for Patients With CKD
Patients with CKD over the age of 50 should receive a dose of PCV13 first, followed by a dose of PPSV23 at least 8 weeks later. Subsequent doses of PPSV23 should follow current PPSV23 recommendations for adults at high risk. The guidelines also mention that the burden of pneumococcal infections in patients with CKD is high, the cost of pneumococcal vaccination is low as compared with the global health costs in this population and there are no data indicating potential disadvantages. Thus, pneumococcal vaccination should be administered to all patients with CKD as early in the disease as possible. The schedule of vaccination to be followed in all patients with CKD is given below.
Adapted from Guidelines for vaccination in patients with chronic kidney disease. 2016.
In case of kidney transplant patients, the guidelines advise that the schedule of immunisation with the vaccines to be followed is as per the recommended schedule for general adults. However, owing to intense immunosuppression following kidney transplant, vaccination should be avoided within 3 to 6 months of transplantation. In addition, for preventing infection in kidney transplant patients, pneumococcal vaccines should be administered to all household contacts, including pets, of the transplant recipients. The ACIP guidelines suggest the following comprehensive approach for optimal vaccine efficacy among immunocompromised adults, which includes kidney transplant recipients:
If a patient receives the first dose of PCV13, it should be followed by PPSV23 about 8 weeks later1
If a patient had received PPSV23 in the past, a PCV13 dose should be administered after at least a year only1
If a patient who has received PPSV23 requires further doses of PPSV23, it should be administered at least 5 years after the last dose of PPSV231
CKD, chronic kidney disease; PCV-7, 7-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal plain polysaccharide vaccine.
Reference:
Please click the Prescribing Information link to view the safety and adverse events information of Prevenar 13®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.
PP-PRV-IND-0661 July 2023
Help protect your adult patients against pneumococcal pneumonia with single-dose administration
Learn more
Efficacy proven by the CAPiTA study
Learn more
The ACIP recommends routine use of PCV13 among adults
Learn more
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.
Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.
Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered medical practitioner*, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.